These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 6809891)

  • 1. The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties.
    Elsworth JD; Sandler M; Lees AJ; Ward C; Stern GM
    J Neural Transm; 1982; 54(1-2):105-10. PubMed ID: 6809891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and pharmacological problems of deprenyl (selegiline) treatment in Parkinson's disease.
    Stern GM; Lees AJ; Hardie RJ; Sandler M
    Acta Neurol Scand Suppl; 1983; 95():113-6. PubMed ID: 6428142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment.
    Karoum F; Chuang LW; Eisler T; Calne DB; Liebowitz MR; Quitkin FM; Klein DF; Wyatt RJ
    Neurology; 1982 May; 32(5):503-9. PubMed ID: 6803190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and pharmacological aspects of (-)-deprenyl treatment in Parkinson's disease.
    Stern GM; Lees AJ; Hardie R; Sandler M
    Mod Probl Pharmacopsychiatry; 1983; 19():215-9. PubMed ID: 6408407
    [No Abstract]   [Full Text] [Related]  

  • 5. Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa.
    Schachter M; Marsden CD; Parkes JD; Jenner P; Testa B
    J Neurol Neurosurg Psychiatry; 1980 Nov; 43(11):1016-21. PubMed ID: 6777463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease.
    Presthus J; Hajba A
    Acta Neurol Scand Suppl; 1983; 95():127-33. PubMed ID: 6428145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease.
    Csanda E; Tárczy M
    Acta Neurol Scand Suppl; 1983; 95():117-22. PubMed ID: 6428143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-deprenyl treatment of on-off phenomena in Parkinson's disease.
    Rinne UK; Siirtola T; Sonninen V
    J Neural Transm; 1978; 43(3-4):253-62. PubMed ID: 745018
    [No Abstract]   [Full Text] [Related]  

  • 9. Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease. A double-blind crossover trial.
    Presthus J; Berstad J; Lien K
    Acta Neurol Scand; 1987 Sep; 76(3):200-3. PubMed ID: 3120487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind trial of R-(-)-deprenyl for the "on-off" effect complicating Parkinson's disease.
    Golbe LI; Duvoisin RC
    J Neural Transm Suppl; 1987; 25():123-9. PubMed ID: 3123598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deprenyl (selegiline) in the treatment of Parkinson's disease.
    Birkmayer W
    Acta Neurol Scand Suppl; 1983; 95():103-5. PubMed ID: 6428140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-deprenyl in the treatment of Parkinson's disease.
    Csanda E; Tárczy M; Takáts A; Mogyorós I; Köves A; Katona G
    J Neural Transm Suppl; 1983; 19():283-90. PubMed ID: 6421993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experiences with L-deprenyl in Parkinsonism.
    Csanda E; Antal J; Antóny M; Csanaky A
    J Neural Transm; 1978; 43(3-4):263-9. PubMed ID: 370348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease.
    Rinne UK
    J Neural Transm Suppl; 1987; 25():149-55. PubMed ID: 3123601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease.
    Birkmayer W; Knoll J; Riederer P; Youdim MB
    Mod Probl Pharmacopsychiatry; 1983; 19():170-6. PubMed ID: 6408405
    [No Abstract]   [Full Text] [Related]  

  • 16. Deprenyl versus placebo in Parkinson disease: a double-blind study.
    Lieberman AN; Gopinathan G; Neophytides A; Foo SH
    N Y State J Med; 1987 Dec; 87(12):646-9. PubMed ID: 3124027
    [No Abstract]   [Full Text] [Related]  

  • 17. (-)Deprenyl in the treatment of decompensated Parkinson's disease.
    Csanda E; Tárczy M; Takáts A
    J Neural Transm Suppl; 1986; 22():247-52. PubMed ID: 3097259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deprenyl (selegiline) in combination treatment of Parkinson's disease.
    Gerstenbrand F; Ransmayr G; Poewe W
    Acta Neurol Scand Suppl; 1983; 95():123-6. PubMed ID: 6428144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deprenyl (selegiline) in the treatment of Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1983; 95():107-11. PubMed ID: 6428141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selegiline in the treatment of Parkinson's disease--long term experience.
    Yahr MD; Elizan TS; Moros D
    Acta Neurol Scand Suppl; 1989; 126():157-61. PubMed ID: 2515721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.